Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2002-9-18
pubmed:abstractText
Irinotecan (CPT-11) is an anticancer agent for the treatment of colon cancer. CPT-11 can be considered as a prodrug, since it needs to be activated into the toxic drug SN-38 by the enzyme carboxylesterase. An approach to achieve tumour specific activation of CPT-11 is to transduce the cDNA encoding carboxylesterase into tumour cells. A secreted form of carboxylesterase may diffuse through a tumour mass and may activate CPT-11 extracellularly. This could enhance the antitumour efficacy by exerting a bystander effect on untransduced cells. In addition a secreted tumour-targeted form of carboxylesterase should prevent leakage of the enzyme from the site of the tumour into the circulation. We have constructed a secreted form of human liver carboxylesterase-2 by deletion of the cellular retention signal and by cloning the cDNA downstream of an Ig kappa leader sequence. The protein was secreted by transfected cells and showed both enzyme activity and efficient CPT-11 activation. To obtain a secreted, tumour-targeted form of carboxylesterase-2 the cDNA encoding the human scFv antibody C28 directed against the epithelial cell adhesion molecule EpCAM, was inserted between the leader sequence and carboxylesterase-2. This fusion protein showed CPT-11 activation and specific binding to EpCAM expressing cells. Importantly, in combination with CPT-11 both recombinant carboxylesterase proteins exerted strong antiproliferative effects on human colon cancer cells. They are, therefore, promising new tools for gene directed enzyme prodrug therapy approaches for the treatment of colon carcinoma with CPT-11.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-10096296, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-10213229, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-10640517, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-10728672, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-11023197, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-11431344, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-11875747, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-1783980, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-1918003, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-2612723, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-3019523, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-3331171, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-3510721, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-5432063, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-7634381, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-7920428, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-8163559, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-8450832, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-857894, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-9180383, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-9193346, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-9541511, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-9597156, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-9766666, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-9815701, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-9815808, http://linkedlifedata.com/resource/pubmed/commentcorrection/12237777-9816097
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:day
9
pubmed:volume
87
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
659-64
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:12237777-Animals, pubmed-meshheading:12237777-Antigens, Neoplasm, pubmed-meshheading:12237777-Antineoplastic Agents, Phytogenic, pubmed-meshheading:12237777-Blotting, Western, pubmed-meshheading:12237777-COS Cells, pubmed-meshheading:12237777-Camptothecin, pubmed-meshheading:12237777-Carboxylesterase, pubmed-meshheading:12237777-Carboxylic Ester Hydrolases, pubmed-meshheading:12237777-Cell Adhesion Molecules, pubmed-meshheading:12237777-Cell Division, pubmed-meshheading:12237777-Cercopithecus aethiops, pubmed-meshheading:12237777-Colonic Neoplasms, pubmed-meshheading:12237777-Drug Screening Assays, Antitumor, pubmed-meshheading:12237777-Gene Expression Regulation, pubmed-meshheading:12237777-Humans, pubmed-meshheading:12237777-Immunoenzyme Techniques, pubmed-meshheading:12237777-Lymphokines, pubmed-meshheading:12237777-Plasmids, pubmed-meshheading:12237777-Polymerase Chain Reaction, pubmed-meshheading:12237777-Prodrugs, pubmed-meshheading:12237777-Sialoglycoproteins, pubmed-meshheading:12237777-Tumor Cells, Cultured
pubmed:year
2002
pubmed:articleTitle
Secreted and tumour targeted human carboxylesterase for activation of irinotecan.
pubmed:affiliation
Division of Gene Therapy, Department of Medical Oncology, Vrije Universiteit Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands. D.Oosterhoff.oncol@med.vu.nl
pubmed:publicationType
Journal Article